Press Release

PhRMA Appoints Dr. David Wheadon To Head Scientific Team

PhRMA January 13, 2009

Washington, D.C. (January 13, 2009) — Citing the important role that innovation plays in creating new medicines for patients, as well as generating new jobs for the U.S. economy, the Pharmaceutical Research and Manufacturers of America (PhRMA) has filled a key leadership position.

Effective at month’s end, Dr. David Wheadon will join PhRMA’s Scientific & Regulatory Affairs team as Senior Vice President. Chosen after an exhaustive national search, Dr. Wheadon’s selection strengthens an already stellar team and reflects PhRMA’s commitment to active engagement with regulatory agencies and congressional leaders, and underscores its commitment to further strengthening the Food and Drug Administration (FDA).

Dr. Wheadon brings more than 20 years experience in the pharmaceutical research industry, encompassing both clinical research and regulatory affairs. Through his various roles, he has built an extensive network among government agencies around the world and has interfaced extensively with U.S. regulatory agencies. He has represented pharmaceutical research companies in various public forums, including testifying before Congress.

Prior to joining PhRMA, Dr. Wheadon served as Vice President of Global Pharmaceutical Regulatory and Medical Sciences at Abbott Laboratories. In this role, he built a global regulatory affairs operation with business as well as research and development responsibilities.

He began his career at Eli Lilly & Company, where he held positions in clinical research and development. For Lilly, Dr. Wheadon was intimately involved in the introduction of selective serotonin reuptake inhibitors as a therapeutic option for many psychiatric disorders. He had significant roles in the development of both an antidepressant and a treatment for schizophrenia.

Following Lilly, Dr. Wheadon held senior clinical and regulatory positions at SmithKline Beecham and GlaxoSmithKline (GSK), where his work included research and development for small molecules and vaccines. He was instrumental in the development, regulatory approval and launch of an antidepressant, a treatment for restless leg syndrome and a treatment for Type II diabetes, along with the transfer of a smoking-cessation therapy from prescription to over-the-counter status. Following the merger of SmithKline Beecham and Glaxo Wellcome, he managed U.S. Regulatory Affairs at GSK.

“Innovation is the engine that ensures that patients have access to medicines that improve public health by permitting patients to live healthier, more productive lives. What’s more, as national leaders recognize, innovation creates a steady source of jobs during these uncertain economic times,” said PhRMA President and CEO Billy Tauzin.

“PhRMA’s leadership team offers an incredible wealth of experience, diversity and continuity. With the appointment announced today, we are even better structured to meaningfully contribute to important debates that impact patients across the globe,” Tauzin said.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $45.8 billion in 2009 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.3 billion in 2009.

PhRMA Internet Address:
For information on how innovative medicines save lives, visit:
For information on the Partnership for Prescription Assistance, visit:
For more information on public health emergencies, visit
For information on the danger of imported drugs, visit: